LGDN:FRA
リガンド・ファーマシューティカルズ
€192.00
arrow_upward
+1.05%(+2.00) 1 日
4月24日, 8:41:05 GMT+2 · EUR
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoLGDN の上位の分析情報を生成しています...
始値
€192.00
高値
€192.00
安値
€192.00
時価総額
45.78億
平均出来高
3.00
取引量
0.00
52 週高値
€195.00
52 週安値
€87.00
従業員数
47
ニュース記事
ウェブの情報から
Xã Vĩnh Công
·
3 週間前
LGND Stock Analysis: Bearish Pressure Amid Market Decline
プロフィール
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
リガンド・ファーマシューティカルズ について